Higher Irradiance in Keratoconus Ectasia (NCT01789333) | Clinical Trial Compass
WithdrawnNot Applicable
Higher Irradiance in Keratoconus Ectasia
United States0Started 2010-09-01
Plain-language summary
The purpose of the study is to see if brighter lights will allow for shortening of the treatment time required to stabilize the eyes of patients with keratoconus or a bulging cornea. The investigators will be comparing the therapeutic effects of two different higher brightnesses of ultra violet light on a riboflavin treated eye. One light will be twice as bright as the other and the exposure time of these brighter lights to deliver equivalent energy to the cornea will be reduced from the standard 30 minutes to 10 and 5 minutes. Riboflavin is vitamin B2 and the investigators are trying to determine if an identical clinical effect can be achieved the brighter treatment lights are used for shorter times. The investigators will also monitor the clinical effect and the status of the cornea to see if additional risks are associated with the brighter light.
Who can participate
Age range16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 16 years of age or older
✓. Having a diagnosis of progressive keratoconus or pellucid marginal degeneration.
✓. Characteristic pattern of deformity as analyzed by the Pentacam map.
✓. Minimal thickness of 350 microns
✓. The ability to sign a written informed consent
✓. States a willingness and ability to comply with schedule for follow-up visits
✓. Subject willing to remove contact lenses prior to evaluation and treatment
✓. History of having undergone a keratorefractive procedure and show:
Exclusion criteria
✕. Eyes classified as either normal or atypical normal,
✕. Corneal pachymetry ≤ 350 microns at the thinnest point in treatment zone measured by Pentacam.
What they're measuring
1
Change in Total Optical Aberrations of the Cornea following Cross-Linking